AU2003286663B2 - Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain - Google Patents

Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain Download PDF

Info

Publication number
AU2003286663B2
AU2003286663B2 AU2003286663A AU2003286663A AU2003286663B2 AU 2003286663 B2 AU2003286663 B2 AU 2003286663B2 AU 2003286663 A AU2003286663 A AU 2003286663A AU 2003286663 A AU2003286663 A AU 2003286663A AU 2003286663 B2 AU2003286663 B2 AU 2003286663B2
Authority
AU
Australia
Prior art keywords
pain
immunomodulatory
immunomodulatory compound
patient
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2003286663A
Other languages
English (en)
Other versions
AU2003286663A1 (en
Inventor
Herbert Faleck
Donald C. Manning
Jerome B. Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2003286663A1 publication Critical patent/AU2003286663A1/en
Application granted granted Critical
Publication of AU2003286663B2 publication Critical patent/AU2003286663B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003286663A 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain Expired - Fee Related AU2003286663B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42100302P 2002-10-24 2002-10-24
US60/421,003 2002-10-24
PCT/US2003/033757 WO2004037199A2 (en) 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

Publications (2)

Publication Number Publication Date
AU2003286663A1 AU2003286663A1 (en) 2004-05-13
AU2003286663B2 true AU2003286663B2 (en) 2009-08-13

Family

ID=32176661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286663A Expired - Fee Related AU2003286663B2 (en) 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

Country Status (13)

Country Link
EP (1) EP1556044A2 (es)
JP (1) JP2006507284A (es)
KR (1) KR20050057672A (es)
CN (2) CN101108185A (es)
AU (1) AU2003286663B2 (es)
BR (1) BR0315609A (es)
CA (1) CA2503536A1 (es)
HK (1) HK1088225A1 (es)
MX (1) MXPA05004182A (es)
NZ (1) NZ540028A (es)
TW (1) TW200503683A (es)
WO (1) WO2004037199A2 (es)
ZA (1) ZA200503240B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CA2603926A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
JP4382735B2 (ja) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
KR20090014393A (ko) * 2006-05-26 2009-02-10 셀진 코포레이션 조합 요법에서 면역조절 화합물을 사용하는 방법 및 조성물
US20110184025A1 (en) * 2006-10-19 2011-07-28 Hensel Jennifer L Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
WO2002080891A1 (en) * 2001-04-06 2002-10-17 A+ Science Invest Ab Use of a tnf inhibitor for the treatment of low back pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69740140D1 (de) * 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6316471B1 (en) * 1996-07-24 2001-11-13 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
WO2002080891A1 (en) * 2001-04-06 2002-10-17 A+ Science Invest Ab Use of a tnf inhibitor for the treatment of low back pain

Also Published As

Publication number Publication date
EP1556044A2 (en) 2005-07-27
CA2503536A1 (en) 2004-05-06
KR20050057672A (ko) 2005-06-16
AU2003286663A1 (en) 2004-05-13
NZ540028A (en) 2009-07-31
HK1088225A1 (en) 2006-11-03
CN101108185A (zh) 2008-01-23
ZA200503240B (en) 2007-11-28
WO2004037199A3 (en) 2004-12-23
CN1732000A (zh) 2006-02-08
MXPA05004182A (es) 2005-06-08
BR0315609A (pt) 2005-08-23
JP2006507284A (ja) 2006-03-02
WO2004037199A2 (en) 2004-05-06
TW200503683A (en) 2005-02-01
CN1326522C (zh) 2007-07-18

Similar Documents

Publication Publication Date Title
US20050203142A1 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
AU2003284979B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20060154880A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
AU2003286663B2 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7612096B2 (en) Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050119194A1 (en) Methods of using and compositions comprising thalidomide for treatment, modification and management of fibromyalgia
US20070161696A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CA2543132A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application